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Abstract
PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification
in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and
biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk
stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-
marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in
96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year
event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR
4.0, p < 0.0001), 29 (HzR 2.7, p < 0.0001), and 79 (HzR 3.5, p < 0.0001) associated with hazard of relapse adjusted for age,
cytogenetics, and WBC. The early (day 15) response associated with CIR5y adjusted for day 29 FCM-MRD, with higher
levels in adults (median 2.4 × 10−2 versus 5.2 × 10−3, p < 0.0001). Undetectable FCM- and/or PCR-MRD on day 29
identified patients with a very good outcome (CIR5y= 3.2%). For patients who did not undergo transplantation, day 79
FCM-MRD > 10−4 associated with a CIR5y= 22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a
clinically useful method for MRD-based treatment stratification in BCP-ALL.
Introduction
Minimal residual disease (MRD) is the single most
important prognostic factor in acute lymphoblastic leu-
kemia (ALL) [1–5], and guides the ALL post-induction
treatment intensity. The current method of choice for
MRD monitoring is real-time quantitative polymerase
chain reaction of T-cell receptor (TCR)/immunoglobulin
(Ig) gene rearrangements (PCR-MRD) [6]. However,
not all patients with precursor B-ALL (BCP-ALL) have
detectable gene rearrangements or sufficiently sensitive
PCR markers, preventing proper risk stratification in
2–14% of patients [2, 7–9]. The possible loss of a marker
during therapy requires the analysis of two PCR markers,
which may further decrease the number of evaluable
patients [2, 7, 8, 10]. Finally, PCR-MRD has a maximum
sensitivity of 10−5 and most commonly a quantitative
range (QR) of 10−4 due to the limit on DNA input [6].
Recently, high-throughput sequencing of TCR/Ig gene
rearrangements (HTS-MRD) has emerged as a promising
and sensitive method for MRD monitoring in BCP-ALL,
but it is not yet fully validated for clinical use [11]. HTS-
MRD has a relatively long turnaround time (4–5 days) and
also requires a high DNA amount. Moreover, around 5%
of the patients still remain without an identifiable MRD
marker [11].
Flow cytometry is the alternative method used for MRD
detection. It has a shorter turnaround time (1 day) and, in
contrast to PCR, identifies the maturation stage and phe-
notypical heterogeneity of the leukemia. In addition, it
provides information on the bone marrow cellular status.
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However, it is less sensitive than PCR, more difficult to
standardize across centers, and requires a high level of
expertise [6, 12]. Although comparative studies of FCM-
versus PCR-MRD have been performed [8, 13–19], few
study protocols have used FCM-MRD as the primary
method for risk stratification in BCP-ALL. Ribera et al.
reported on FCM-MRD-guided stratification to HSCT ver-
sus chemotherapy after early consolidation for 179 patients
enrolled in five centers participating in the PETHEMA-
ALL-AR-03 trial [20]. In the AALL0232 study by the
Children’s Oncology Group FCM-MRD performed in two
reference centers was used to risk stratify patients after first
induction [21, 22]. Hitherto, no data are published on the
clinical feasibility of FCM-MRD in an international, mul-
ticenter setting.
In this study, we show that FCM-MRD performed in 18
Nordic and Baltic centers is a valid approach for MRD
detection at early and late stratifying time points provid-
ing prognostic value in relation to patient outcome in
patients treated according to the Nordic Society of




In this study, we included 1298 children and 189 adults
(<45 years of age) with BCP-ALL from Denmark, Estonia,
Finland, Iceland, Lithuania, Norway, and Sweden, treated
and monitored in the NOPHO ALL2008 protocol between
July 1, 2008 and February 29, 2016 [23]. Patients with
ambiguous lineage ALL [24], ALL predisposing syn-
dromes, or pretreated with antileukemic agents, including
corticosteroids, for >1 week prior to the diagnosis were
excluded from the study [25]. In addition, patients with B-
lymphoblastic lymphoma and Philadelphia chromosome
positive BCP-ALL were excluded. The regional or national
ethics committees approved the protocol, and informed
consent was obtained according to the Declaration of
Helsinki
Protocol and MRD-based stratification
The NOPHO ALL2008 treatment and monitoring of BCP-
ALL patients have been previously described [23]. In short,
patients were stratified at diagnosis to induction therapy
with either dexamethasone (10 mg/m2/day for 3 weeks) or
prednisolone (60 mg/m2 for 4 weeks), weekly vincristine,
two doses of doxorubicin (40 mg/m2 on days 1 and 22) with
intrathecal methotrexate (or triple therapy for patients with
central nervous system involvement). Bone marrow
sampling was performed on days 0, 15, and 29 (end of
induction, EOI) of therapy, and on day 79 (for standard risk
(SR) and intermediate risk (IR) patients) or prior to high-
risk (HR) blocks until MRD was undetectable (Fig. 1).
Treatment stratification was performed on day 15 for +/−
early HR-block therapy, on EOI (day 29) for SR/IR/HR
consolidation or HSCT, and on day 79 (SR/IR) or after
the second HR-block (HR) for +/− HSCT as described in
Fig. 1.
MRD analysis and retrospective revision of MRD
data
MRD was measured by FCM-MRD using protocol-defined
six-color panels for identification and monitoring of the
leukemia-associated immunophenotype (LAIP) according
to the NOPHO ALL2008 guidelines (Supplementary
methods and Table S1), and by real-time quantitative PCR
using clone-specific TCR/Ig primers according to the
EuroMRD guidelines [26, 27]. All patients were evaluated
for MRD marker informative status by both FCM and PCR
at diagnosis. At MRD timepoints, the protocol specified that
the first aspirate should be used for FCM- and PCR-MRD to
avoid hemodilution and subsequent differences in assess-
ment of blast concentration. The bone marrow material was
split equally for FCM- and PCR-MRD. MRD-based treat-
ment stratification was performed according to FCM-MRD,
when an informative LAIP was identified. If not, patients
were stratified by PCR-MRD, when specific and sufficiently
sensitive (QR <10−3) markers were available. As a standard,
two PCR-markers were required, but when not identified,
one sensitive marker could be accepted. The FCM-MRD
analysis was performed in 18 centers and PCR-MRD in 7
centers. Three centers performed FCM- and PCR-MRD in
parallel at all timepoints.
FCM- and PCR-MRD results were defined as discrepant
when it would result in a different risk stratification at 10−3
level on day 29 or detectable/undetectable. The latter was
defined as undetectable MRD by one method but detectable
≥10−4 by the other, with a >2.5-fold higher value than the
detection limit of the method with undetectable MRD, to
account for the variation of the detection limits of the
respective methods. For patients with discrepant day 29
FCM- and PCR-MRD results, FCM-files and PCR data
were reviewed by experienced members of the Nordic flow
cytometry group and the national PCR coordinators to
explain the discrepancy.
Statistical analysis
The main clinical outcomes of this study were 5-year event-
free survival (EFS5y) and 5-year cumulative incidence of
relapse (CIR5y). Survival analysis with time since diagnosis
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as the underlying timescale and delayed entry at time of
MRD-measurement was used for analysis of the association
between MRD and outcome. For analysis of outcome after
HSCT, time since HSCT comprised the underlying time-
scale. For the analysis of day 15/29 MRD and prognosis,
patients stratified directly to HSCT based on day 29 MRD
were excluded, as this significantly changed their prognosis.
Patients stratified to HSCT on day 79/after the second HR-
block were censored at time of HSCT. Death and secondary
malignancy were treated as competing events in the analyses
of relapse, and for the day 15 analyses, induction failure was
additionally considered a competing event. The
Kaplan–Meier method was used to determine EFS, and the
Aalen–Johansen estimator to determine CIR. Survival
curves were compared using the log-rank test, and CIR5y
compared using the Wald test. Cause-specific Cox regres-
sion with delayed entry at time of MRD measurement was
used to determine the association between MRD
and the hazard of relapse adjusting for age group (<10 years,
10–17 years, ≥18 years), WBC (</≥100 × 109/L), cytoge-
netic risk group (cytogenetic standard risk (SR CG): high
hyperdiploidy (51–67 chromosomes) or t(12;21)(p13;q22)).
Cytogenetic intermediate risk (IR CG): dic(9;20)(p11–13;
q11) or t(1;19)(q23;p13), or intrachromosomal amplification
of chromosome 21. Cytogenetic high risk (HR CG): KMT2A
rearrangement (KMT2A-r) or hypodiploidy (23–39 chro-
mosomes). B-other: patients with no stratifying genetic
aberration, normal genetic findings, or with a not informa-
tive cytogenetic result), and in analyses of days 15 and
79 MRD also adjusting for day 29 MRD (</≥10−3).
The proportional hazards assumption and linearity of
quantitative variables were evaluated using tests based on
sums of cumulative martingale residuals [28]. Spearman’s
correlation coefficient was used to explore the association
between FCM- and PCR-MRD values. Fisher’s exact
test was used for comparison of categorical variables
between groups. Cohen’s kappa for dichotomized MRD
values, and Bland–Altman plots with limits of agreement for
quantitative MRD values were used to assess agreement. CI
represents 95% confidence intervals. P values < 0.05 were
considered significant. Statistical analyses were performed in
SAS version 9.4 and R version 3.6.0.
Fig. 1 Stratification algorithm and MRD data for patients with
BCP-ALL in the NOPHO ALL2008 protocol. Bone marrow sam-
pling was performed on days 0, 15, and 29 (end of induction, EOI) of
therapy, and on day 79 (for SR and IR patients) or prior to HR blocks
until MRD was undetectable (for HR patients) (arrows). Patients with
HR CG (KMT2A-r or hypodiploidy) entered the algorithm of patients
in the +dexamethasone induction. Treatment stratification was per-
formed at EOI to SR/IR/HR consolidation or HSCT. Patients with
WBC <100 at diagnosis and no IR/HR CG (IR CG: dic(9;20), iAMP21
or t(1;19)) were stratified to SR by day 29 MRD <10−3 or to IR by
MRD 10−3≤ to <5 × 10−2, while patients with WBC >100 and no HR
CG were stratified to IR by MRD <10−3 or to HR by MRD
10−3≤ to <5 × 10−2. Stratification to SR/IR was not an option for
patients with HR CG or to SR for those with IR CG. Patients with non-
available day 29 MRD for non-HR cytogenetic groups entered the IR
risk group at end of induction. Patients were stratified to HSCT if day
29 MRD was ≥5 × 10−2 or if day 79 (for SR/IR patients) or MRD after
the second HR-block was ≥10−3. Further, patients with WBC ≥100
were stratified directly to HR-block therapy at day 15 by FCM-
MRD ≥25%. Three patients had missing data for stratification at day
29. Eight patients were excluded from the day 29 analyses with the
bone marrow sample date being >50 days from time of diagnosis. CG
cytogenetic group, FCM-MRD flow cytometry-based minimal residual
disease, HR high risk, IR intermediate risk, PCR-MRD polymerase-
chain-reaction-based minimal residual disease, SCT hematopoietic
stem cell transplantation, SR standard risk.
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Results
Feasibility of FCM-MRD
Information on FCM or PCR marker informative status at
diagnosis was registered in 1455 patients (Tables 1 and S2).
Of these, an informative LAIP for MRD monitoring was
identified in 1399 patients (96.2%). Of the remaining, 43
had an informative PCR marker. Only two patients (0.14%
of total) had a non-informative LAIP and also lacked a
sensitive antigen receptor gene rearrangement, while 11
lacked an informative marker due to other technical reasons
or insufficient sample material (Table S2). Among the 31
patients with a non-informative LAIP, t(1;19) (n= 4,
p= 0.01), dic(9;20) (n= 3, p= 0.02), and hypodiploidy
(n= 3, p= 0.01) were overrepresented, while high hyper-
diploidy was underrepresented (n= 2, p= 0.002) compared
to remaining cases.
EOI MRD determined by FCM and clinical outcome
The overall EFS5y was 86.1% (CI 84.1–88.1%) with a
CIR5Y of 9.5% (CI 7.8–11.3%) in this cohort of 1487
patients (1298 children and 189 adults).
The day 29 FCM-MRD was associated with EFS and CIR
(Fig. 2A, B). In a multivariable analysis including the risk
factors of the protocol, FCM-MRD>10−3 at EOI, WBC
>100, older age groups, and IR/HR/B-other CG were all
predictors of relapse (Table 2). Figure 2C illustrates the
combined effects on EFS of WBC and FCM-MRD.
In patients stratified to SR consolidation by FCM-MRD
<10−3 (n= 767), we found no difference in EFS5y for
patients with FCM-MRD ≥10−4 (EFS5y 92.1, CI 88.1–96.3,
n= 527) and <10−4 (EFS5y 91.1, CI 88.3–94.0, n= 240,
Fig. 2A). For those stratified to IR consolidation by FCM-
MRD <10−3 (initial WBC >100, n= 47), patients with
FCM-MRD ≥10−4 had an EFS5y of 77.8% (CI 57.1–100%,
n= 18) versus EFS5y 92.0 (CI 81.7–100%, n= 29) for
those with FCM-MRD <10−4.
Patients with FCM-MRD of 10−3 to <5 × 10−2 on day 29
and B-other had a poor outcome (EFS5y 69.3%, CI 59–81%,
CIR5Y 28.8%, CI 18–40%, Fig. 2D). This group consisted
of 114 patients, of which 41 (36%) were adults. The B-other
adult ALL-IR group contained 58 of the 84 adult ALL-IR
patients and included all the 13 relapses among the adult
ALL-IR patients (p= 0.0001, Wald test for comparison of
CIR5y for B-other versus non-B-other adult ALL-IR).
Among the 17 adult ALL-IR patients with MRD <10−3,
three experienced relapse.
Undetectable MRD by FCM and/or PCR defines very
good responders at EOI
Out of 331 patients with MRD results by both methods, 123
had undetectable day 29 MRD by FCM- and/or PCR with an
overall CIR5Y of 3.2% (CI 1.9–6.85). Among the 62 with
undetectable day 29 MRD by both methods, two experienced
relapse (CIR5Y 4.9%, CI 0–11.8%, FCM-MRD sensitivity 6 ×
10−5/8 × 10−5, PCR-MRD sensitivity 1 × 10−5/5 × 10−4 for the
two). Both also had undetectable FCM- and PCR-MRD on day
79. Among 48 patients with undetectable FCM-MRD, but
detectable PCR-MRD, there was one relapse (CIR5Y 2.2%, CI
0–6.4%, FCM-MRD sensitivity 2 × 10−5), and none among the
13 with undetectable PCR-MRD and detectable FCM-MRD.
There was no association between undetectable MRD with
subsequent relapse and specific cytogenetic aberrations.
Early response predicts clinical outcome
The day 15 FCM-MRD level was associated with the out-
come with clear differences in EFS and CIR using a cutoff
Table 1 Patient characteristics.
Clinical characteristics
Age 4 (2–11, 1–45) years
Gender 781/706 (52.5/47.5%) male/
female
White blood cell count (WBC) at
diagnosis












B-other (no stratifying genetic
aberration or not informativea)
493 (33.2%)
CNS status at diagnosis 1326/114/42/5 (89/8/3/0%)
CNS1/CNS2/CNS3/n.a.
Follow up time for patients in
remission
51 (31–75, 0.6–103) months
For continuous variables, median (IQR, range) is given, for categorical
variables, absolute number (percentage) is given. CNS1: no malignant
blasts detected in the cerebrospinal fluid (CSF) by cytospin. CNS2:
malignant blasts detected in the CSF by cytospin and CSF leukocyte
count <5. CNS3: malignant blasts detected in the CSF by cytospin and
CSF leukocyte count ≥5.
aFor 40/493 patients classified as B-other, ≥1 of the cytogenetic tests
were missing. There were no positive findings in the tests that were
performed for this group and none lacked all analyses. Reperforming
analyses excluding these patients from the B-other group did not
change the conclusions of the study.
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level of 10−3. Patients with FCM-MRD <10−3 had an EFS5y
of 92.0% (CI 89.2–95.0%) and a CIR5y of 3.9% (CI
1.7–6.1%, n= 432) whereas those with FCM-MRD ≥10−3
to <5 × 10−2 had an EFS5y of 86.5% (CI 83.5–89.7%,
n= 636, p= 0.0058) and a CIR5y of 9.9% (CI 7.1–12.7%,
p= 0.001, Fig. 3A, B). When adjusting for WBC, age, and
CG, the day 15 FCM-MRD ≥10−3 to <5 × 10−2 had a
hazard ratio (HzR) of 4.0 (CI 2.1–7.7) for relapse compared
with FCM-MRD <10−3 (p < 0.0001). When including the
day 29 FCM-MRD in a multivariable analysis, the day 15
response remained associated with the hazard of relapse
(HzR 3.5 (CI 1.8–6.9) for FCM-MRD ≥10−3 to <5 × 10−2
on day 15 versus FCM-MRD <10−3, p= 0.0003).
The early response was associated with age (FCM-MRD
median 2.4 × 10−2 in adults versus 5.2 × 10−3 in children,
p < 0.0001) with adults having a significantly higher
proportion of patients with MRD ≥5 × 10−2 than children
<10 years on day 15 (Fig. 3C). This difference was related
to cytogenetic subtypes with the SR CG subtypes being
more frequent among the children <10 years and
Fig. 2 Day 29 FCM-MRD level, WBC, cytogenetics, and EFS.
A EFS by day 29 FCM-MRD level. Patients are grouped by day 29
FCM-MRD in log10 intervals. B EFS and day 29 FCM-MRD level,
cutoff level 10−3. C EFS by WBC (cutoff level 100 × 109/L) and day
29 FCM-MRD (cutoff level 10−3). D EFS by cytogenetic group
and day 29 FCM-MRD (cutoff level 10−3). SR CG comprise high
hyperdiploidy and t(12;21) while IR CG comprise dic(9;20), iAMP21,
and t(1;19). The HR CG comprises KMT2A-r and hypodiploidy.
B-other comprises patients with no stratifying genetic aberration,
normal genetic findings, or with a not informative cytogenetic result.
CG cytogenetic group, CIR cumulative incidence of relapse, EFS
event-free survival, HR high risk, IR intermediate risk, MRD minimal
residual disease, SR standard risk.
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displaying low day 15 FCM-MRD, while the B-other
group was most frequent among the older children and
adults, showing clear differences in MRD levels among
age groups (Fig. 3D).
Persistent residual disease by FCM-MRD in non-
transplanted SR/IR patients is associated with poor
outcome
In the ALL2008 protocol, patients were stratified to HSCT
by MRD ≥10−3 on day 79 or after the second HR-block. We
therefore examined the clinical outcome of patients with
MRD <10−3 at these two timepoints. Patients with day 79
FCM-MRD of 10−4 to <10−3 had a significantly higher
CIR5y (22.1%, CI 10.8–33.5%, n= 68) compared with
patients with day 79 FCM-MRD <10−4 (7.5%, CI
2.1–12.8%, n= 110) or undetectable (6.3%, CI 4.5–8.2%,
n= 999, Fig. 4A, p= 0.0087 for FCM-MRD 10−4 to <10−3
versus <10−4/undetectable).
These findings were confirmed by day 79 PCR-MRD
values. For patients with an undetectable PCR-MRD
(n= 214), the CIR5y (7.1%, CI 3.1–11.2%) was compar-
able to that of undetectable day 79 FCM-MRD. The number
of patients with detectable MRD by PCR was too small for
analyses (n= 35 with PCR-MRD <10−4, n= 29 with PCR-
MRD of 10−4 to <10−3), and we thus combined FCM- and
PCR-MRD results, selecting the higher value of the two.
This confirmed that patients with MRD of 10−4 to <10−3 on
day 79 had a significantly higher CIR (Fig. 4B).
After adjusting for WBC, age, and cytogenetics, the
day 79 FCM-MRD remained associated with a higher
hazard of relapse (HzR 3.5, CI 1.9–6.4, p < 0.0001) for
day 79 FCM-MRD of 10−4 to <10−3 compared with
undetectable FCM-MRD (n= 1171). Further adjusting
for the day 29 FCM-MRD, the day 79 FCM-MRD
remained associated with relapse (HzR 2.8, CI 1.5–5.3,
p= 0.001 for FCM-MRD of 10−4 to <10−3 versus <10−4/
undetectable).
After the second HR-block, no difference in outcome was
demonstrated between patients with undetectable FCM-MRD
(CIR5Y 17.3%, CI 6.7–27.6%, n= 57) and patients with
detectable FCM-MRD<10−4 (CIR5Y 17.4% (CI 0–35.4%,
n= 18). Only five patients had FCM-MRD of 10−4 to <10−3,
two of whom experienced relapse. PCR-MRD results after the
second HR block were available for 22 patients who did
not undergo HSCT. Of these, 16 had undetectable MRD
(0 relapses). Of five with PCR-MRD<10−4, three experi-
enced relapse.
MRD >10−3 on day 79 was detected in 33 patients
either by FCM- or PCR-MRD of which 15 underwent
HSCT. Three of the non-transplanted patients and two of
the transplanted patients experienced relapse. After the
second HR-block, seven patients had FCM-MRD >10−3.
Of these, one did not undergo HSCT and experienced
relapse, and six underwent HSCT, of which four experi-
enced relapse.
MRD and outcome after HSCT
A total of 89 patients underwent HSCT in CR1, 74 of whom
were transplanted based on a stratifying MRD value (48 by
FCM only, 25 by concordant FCM and PCR, one by PCR
only). The 89 had an overall EFS5y from time of trans-
plantation of 73.3% (CI 63.1–85.3%) with a CIR5Y of
19.5% (CI 9.3–29.8%).
Only 9/89 HSCT patients were stratified early (day 15) to
HR-block therapy based on a combination of HR cytoge-
netics/WBC>100 and day 15 MRD>2.5 × 10−1. These
patients had a CIR5Y after HSCT of 51.9% (CI 14.2–89.5%).
In comparison, patients not stratified to early HR therapy had
a CIR5Y after HSCT of 15.9% (5.6–26.2%).
FCM- and PCR-MRD results are highly comparable
PCR-MRD and FCM-MRD were performed in parallel in
352 samples taken at EOI. There was a strong correlation
between FCM and PCR-MRD levels on days 15 (r= 0.77,
p < 0.0001, n= 153) and 29 (r= 0.83, p < 0.0001, n= 183,
Fig. 5). Furthermore, there was a good agreement between
the methods around the day 29 stratification cutoff level of
10−3 (Cohen’s kappa 0.77, CI 0.69–0.84, n= 331). At later
timepoints there were too few patients with quantifiable
MRD by both methods for reliable comparison (day 79
n= 21, after the second HR-block n= 2).
Table 2 Risk factors for relapse in BCP-ALL.
Variable HzR (95% CI) p value
EOI FCM-MRD > 10−3 2.7 (1.8–4.1) <0.0001
WBC ≥ 100 2.6 (1.5–4.5) 0.0006
IR CG 2.9 (1.4–6.4) 0.006
HR CG 3.9 (1.7–9.3) 0.002
B-other 2.8 (1.7–4.8) 0.0001
Children 10–17 years 1.9 (1.1–3.3) 0.02
Adults 18–45 years 2.4 (1.4–4.1) 0.002
Multivariable cause-specific Cox regression analysis of time to
relapse. Death and secondary malignancy were considered competing
risks and censored at the time point of event. Reference groups: FCM-
MRD < 10−3, WBC <100, SR CG and children <10 years. N= 1314.
The SR CG comprises patients with high hyperdiploidy or t(12;21).
The IR CG comprises patients with t(1;19), dic(9;20), or iAMP21. The
HR CG comprises patients with KMT2A-r or hypodiploidy. B-other
comprises patients with no stratifying genetic aberration, normal
genetic findings, or with a not informative cytogenetic result.
CG cytogenetic group, EOI end of induction, FCM-MRD flow
cytometry-based minimal residual disease, HR high risk, IR inter-
mediate risk, SR standard risk, WBC white blood cell count.
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On day 29, the percentage of patients with detected MRD
by FCM of the patients with MRD detected by PCR (FCMdet/
PCRdet) was 81.2%, whereas it was 94.1% for the reverse ratio
(PCRdet/FCMdet), and the overall percentage of discordant
cases was 18.1% (Fig. S1). FCM- and PCR-MRD median
sensitivity/QR for stratifying time points is shown in Table S3.
In total, FCM did not detect MRD in 559 patients on day 29.
Median sensitivity for the patients without detectable FCM-
MRD and with detectable FCM-MRD was comparable.
(4.8 × 10−5 (IQR 3.1–8.8 × 10−5) versus 4.6 × 10−5 (IQR
3.0–7.4 × 10−5), p= 0.09, n= 1414). The FCM-MRD sensi-
tivity increased by calendar year, indicating that more cells
were acquired over the years of the protocol.
Discrepant results were obtained in 44 samples (Table S4).
The FCM- and PCR-MRD led to discrepant EOI stratification
in 33 patients (28 with FCM<10−3, five with PCR<10−3).
Six of these experienced a relapse, all of whom had
FCM-MRD<10−3. Four out of these six patients (1.2% of
total) were stratified as SR patients based on the FCM-MRD
result. In one of the six patients, no MRD was detected by
FCM, which might be explained by the lack of a fully infor-
mative LAIP although the sensitivity was 2.9 × 10−5. In the
other five patients with discrepant results and relapse, FCM-
MRD was detected and ranged between 10−3 and 10−4. Mar-
ker modulation was observed in two of these patients, one of
which had KMT2A-r with loss of CD19 expression (Fig. 6A).
Insufficient hemolysis compromising the analysis was observed
in 2, while in one patient no cause could be identified. Among
the 44 discrepantly stratified cases, KMT2A-r (n= 5, p= 0.02)
and B-other (n= 25, p= 0.001) were overrepresented.
PCR-MRD-related causes for discrepancy included poor
sensitivity and/or QR and the presence of subclones that
were not identified at diagnosis and became dominant
during treatment (Fig. 6B).
Fig. 3 Day 15 FCM-MRD association with outcome and age.
A EFS and day 15 FCM-MRD level, grouped by 10−3. B CIR and day
15 FCM-MRD level, grouped by 10−3 and 2.5 × 10−1, the latter being
the cutoff level for an early stratification to HR risk therapy. C Day
15 FCM-MRD association with age. **p < 0.01, ***p < 0.001,
Fischer’s exact test. D Day 15 FCM-MRD association with age by
the cytogenetic risk group, showing that CG low risk in children
<10 years as well as patients defined as B-other contribute the most to
the age-related differences seen in C. CG low risk includes patients
with high hyperdiploidy or t(12;21), while CG medium/high risk
includes patients with dic(9;20), t(1;19), iAMP21, KMT2A-r, and
hypodiploidy. B-other includes patients with no stratifying genetic
aberration, normal genetic findings, or with a not informative cyto-
genetic result. CG cytogenetic group, CIR cumulative incidence of
relapse, EFS event-free survival, MRD minimal residual disease.
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Discussion
The NOPHO ALL2008 study is the first to apply FCM-
MRD-guided risk stratification of patients with BCP-ALL
in a large, multi-MRD-center setting. We demonstrate
excellent patient outcomes, comparable to protocols using
PCR‐MRD-based stratification [4], with an EFS5y of 86.1%
and a CIR5Y of 9.5% in a mixed cohort of children and
adults. Furthermore, >96% of patients could be followed by
FCM-MRD and an informative MRD marker was obtained
for >99.8% of patients with relevant diagnostic material
when combining FCM- and PCR-MRD.
The early (day 15) FCM-MRD response associated with
relapse independent of the EOI response. This is in line with
Fig. 4 Day 79 MRD and outcome in patients not stratified for
HSCT. A CIR by day 79 FCM-MRD in patients not stratified for
HSCT (MRD <10−3) showing that patients with MRD levels of 10−4
to <10−3 on day 79 had a significantly higher CIR. B CIR by day 79
MRD in patients not stratified for HSCT. The higher value of FCM
and PCR-MRD was selected, if results from both methods were
available. Patients with an MRD of 10−4 to <10−3 on day 79 had a
significantly higher CIR (21.7%, CI 11.3–32.1%, n= 86) compared to
those with detectable MRD <10−4 (10.7%, CI 4.9–16.4%, n= 137) or
undetectable MRD (5.8%, CI 4.0–7.6%, n= 987, p= 0.0047 for MRD
of 10−4 to <10−3 versus <10−4/undetectable). CIR cumulative inci-
dence of relapse, EFS event-free survival, FCM-MRD flow cytometry-
based minimal residual disease, PCR-MRD polymerase-chain-
reaction-based minimal residual disease.
Fig. 5 MRDmeasurements by FCM and PCR days 15 and 29. A, B
Association between FCM- and PCR-MRD on day 15 (n= 186). Of
the 186 patients, 153 had quantifiable MRD by both methods, which
correlated strongly (r= 0.77, p < 0.0001). PCR-MRD was higher than
FCM-MRD (mean 26% higher, limits of agreement −160–212%,
Bland–Altman (B)). C, D Association between FCM- and PCR-MRD
on day 29 (n= 331). MRD was detectable by both methods in 183
patients, showing a strong correlation (r= 0.83, p < 0.0001). PCR-
MRD was higher than FCM-MRD (mean 42% higher, limits of
agreement −123–207%, Bland–Altman (D)). FCM flow cytometry,
LOD limit of detection, MRD minimal residual disease, PCR poly-
merase chain reaction, QR quantitative range.
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Basso et al., who studied 815 patients with FCM-MRD
performed on day 15 of induction after a 7-day prednisolone
monotherapy [29], but in contrast with Short et al., who
examined the day 14 response on EFS in 389 adult ALL
patients [30]. This discrepancy could be due to cutoff level
variations, or to EFS versus CIR as outcome. We further
found that a higher percentage of adults and children >10
years had a poor early response, in particular patients with
B-other ALL. Accordingly, age-related differences in
MRD levels have been shown also at EOI by us and others
[23, 31].
We previously reported a poor EFS5y for adult ALL-IR
patients [23]. Here we show that high MRD on day 29 in B-
other patients is more common in adults and is associated
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with a poor outcome. Notably, we found that all relapses
among the adult ALL-IR patients occurred in the B-other
subgroup. The higher relapse rate in this subgroup is likely
due to the higher proportion of HR BCP-ALL disease
entities such as Ph-like and MEF2D-rearranged BCP-ALL
[32–34], which are more common in adults and have a poor
outcome with conventional chemotherapy [35, 36]. Like-
wise, the association of age and high MRD on day 15 can
be explained by the disease biology of B-other. Including
testing for HR BCP-ALL genetics might improve prognosis
for these patients by allowing the tailoring of MRD cutoff
levels by genetics [37, 38] and by adding tyrosine kinase
inhibitors to conventional therapy [39].
For SR/IR patients, the late (day 79) MRD response even
at levels below 10−3 (above which patients were stratified to
HSCT) was clearly associated with relapse, suggesting
stratification with a lower cutoff could be of value. This is
consistent with Borowitz et al. who found 10−4 to dis-
criminate well with regard to EFS in 186 patients at week
12, albeit without MRD-based stratification at this time-
point, thus including patients with MRD ≥10−3 in the
patient group with MRD ≥10−4 [21]. In HR patients, 10−3
[2], 5 × 10−4 [20], and 10−4 [3, 40] have previously been
suggested as cutoff levels for late response. We had few
patients with MRD of 10−4–10−3 after the second HR-
block, but there was no difference in outcome for patients
with MRD <10−4 and undetectable MRD, with a CIR5Y of
17% for both.
The proportion of discrepant cases (FCMdet/PCRdet and
PCRdet/FCMdet) declined from the early to later timepoints,
corresponding to more patients having a low/undetectable
MRD by one or both methods as treatment progressed. We
found a day 29 FCMdet/PCRdet similar to what Theunissen
et al. found for a threefold higher number of acquired cells
[41]. The low day 15 FCMdet/PCRdet (Fig. S1) could be
explained by the relatively low number of cells acquired on
day 15, Thus, the predictive effect of low/undetectable
MRD by FCM is likely underestimated in this cohort, and
further studies on an early identification of the very good
responders are warranted.
The EOI FCM-MRD level was closely associated with
relapse risk, regardless of other risk factors, and a stratifi-
cation cutoff level of 10−3 was appropriate for the bulk of
patients stratified to SR/IR. Further, only four patients
stratified to SR by FCM-MRD at EOI, but to IR by PCR-
MRD, experienced relapse. Notably, only three centers
routinely performed both FCM- and PCR-MRD, and so the
FCM-MRD prognostic value in comparison to PCR was
likely underestimated, since PCR-MRD was only per-
formed in the remaining centers, when the FCM-MRD was
not informative. Our review of the discrepant cases revealed
a not fully informative/heterogeneous LAIP, insufficient
number of cells, and marker modulation (including CD19
loss in KMT2A-r cases) to be common reasons for an
underestimation of the MRD by FCM. An association
between cytogenetic subgroup and LAIP quality was also
observed for the high hyperdiploid cases, who were
underrepresented among patients with a non-informative
LAIP. This is likely due to the frequent overexpression of
CD123 in this group [42], as CD123 is a very informative
marker for FCM-MRD monitoring [42].
PCR-MRD is a sensitive, standardized method with
extensive, published data for risk stratification in BCP-ALL,
but challenges remain. Not all patients have suitable PCR
markers for monitoring, loss/gain of subclones are difficult
to discover as PCR-MRD does not provide biological
insight, QR and sensitivity are firmly limited by input DNA
amount, and early (day 15) monitoring is not possible, as
markers are not yet ready for implementation [6]. FCM-
MRD is fast, provides information on intra-leukemic het-
erogeneity, and allows for monitoring of patients without
gene rearrangement, thus solving most challenges of PCR-
MRD. Disadvantages of FCM-MRD are the limited sensi-
tivity, high analytical expertise, and lack of informative
markers in some patients. However, these could be
improved by the acquisition of more cells [41] and imple-
mentation of broader panels, and perhaps in time with
technical developments like spectral FCM and bioinfor-
matics. In this protocol, the median EOI FCM-MRD sen-
sitivity was 4.7 × 10−5, corresponding to only 215,000
analyzed cells, and future protocols are likely to show an
even better predictive value of FCM-MRD. It is therefore
crucial to keep performing FCM-MRD and PCR-MRD in
combination to continuously assess the value of both, as
technological progress is made.
The combination of MRD methods in clinical protocols
will also be a topic of discussion as HTS-MRD gains ground.
Fig. 6 Two patient cases discrepantly stratified by FCM and PCR.
A KMT2A-r BCP-ALL. Classically CD10neg/CD20neg with broad
CD19 expression at diagnosis, where the majority of blasts exhibit
NG2 expression and a smaller subpopulation CD34pos expression.
During treatment there is partial loss of CD19 expression. For days 15
and 29, gating (blue) on blasts is done on NGSpos/CD33neg MRD
population (plot not showed). Day 15 FCM-MRD= 1.08% and day 29
FCM-MRD= 0.01% versus day 29 PCR-MRD 1.0%, indicating NG2
only partly informative/additional NG2 loss during treatment in
addition to CD19 decreased expression. B BCP-ALL exhibiting
CD10pos and CD20broad expression at diagnosis with a smaller
subpopulation, amounting to ~3% of the total blast population, exhi-
biting CD34 expression. During treatment there is a distinct treatment
response on the CD34neg dominating subpopulation but continued
persistence of the CD34pos subpopulation displaying a poor treatment
response; day 15 FCM-MRD= 0.3% and day 29 FCM-MRD= 0.32%
with decreasing CD38 expression and increasing CD34 expression.
Neither of the two PCR markers used were able to detect the CD34pos
subpopulation (day 29 PCR-MRD undetectable, QR 3 × 10−5), com-
prising too low a fraction of total blasts at diagnosis to be identified
when screening for TCR/Ig gene rearrangements.
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HTS-MRD shows promise as a highly sensitive method for
MRD-monitoring [11] and a potential replacement of PCR-
MRD, as both methods detect TCR/Ig gene rearrangements.
However, HTS-MRD is yet to be evaluated prospectively in
clinical studies and is currently not useful for patients without
detectable gene rearrangements [11, 43]. Whether the use of
leukemia-specific targets will eventually allow for HTS-MRD
monitoring in these patients as well, or if FCM-MRD will still
be needed, is unclear. The present study shows that com-
bining MRD methods and stratifying by the most informative
method allows for MRD monitoring in all patients and
ensures that any “blind spots” of one can be compensated for
by the other. However, sufficient bone marrow material for
analysis is an important prerequisite of patient stratification to
the very low risk group, regardless of the MRD method
applied. Thus, the balance between reaching adequate MRD
sensitivity and achieving the advantages of a simultaneous
analysis by two methods is difficult to find, as the bone
marrow cells for analysis at MRD timepoints are limited.
Future studies involving monitoring by multiple methods are
warranted to clarify this issue.
In conclusion, we demonstrate proof-of-concept for
FCM-MRD as a primary stratification method in BCP-ALL
in a multicenter setting. Clinical outcomes are associated
equally with FCM and PCR-MRD and the two methods in
combination ensure an accurate monitoring of all patients
with BCP-ALL. Future protocols using an increased num-
ber of acquired cells and 8–10 color panels will show
whether FCM-MRD can reach the sensitivity necessary to
also identify patients with a very low relapse risk. This
would offer the potential to reduce therapy intensity in these
patients. Also, more sensitive FCM-MRD could give
additional prognostic information already on day 15, pos-
sibly allowing stratification at this timepoint.
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